MARSHALL WACE, LLP

Position in PMVP — PMV Pharmaceuticals, Inc.

CIK 1318757 LONDON, X0

Position in PMVP

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$538,275

-$43,082 QoQ

Shares Held

434,093

-6.7% QoQ

Ownership

0.814%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2020

13 quarters on record

Voting authority Sole 0% Shared 100% None 0%

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $2,756,303,735 across 280 Biotechnology names. PMVP ranks #220 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	1,099,318	$363,731,344
2	VRTX	Vertex Pharmaceuticals Inc / Ma	317,058	$141,579,078
3	INCY	Incyte Corp	1,253,138	$117,945,347
4	RPRX	Royalty Pharma plc	2,120,692	$101,729,594
5	RCUS	Arcus Biosciences, Inc.	3,761,437	$81,247,039
6	PTGX	Protagonist Therapeutics, Inc	628,075	$66,199,104
7	ROIV	Roivant Sciences Ltd.	2,246,943	$62,240,320
8	COGT	Cogent Biosciences, Inc.	1,600,168	$61,590,466

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$538,275	434,093	-6.7%	Shares	Other	2026-05-15
2025-12-31	$581,357	465,086	-24.1%	Shares	Other	2026-02-13
2025-09-30	$857,676	612,626	+5462.2%	Shares	Other	2025-11-13
2024-12-31	$16,631	11,014	-82.1%	Shares	Other	2025-02-13
2024-09-30	$91,919	61,691	+378.2%	Shares	Other	2024-11-14
2024-06-30	$20,898	12,900	-90.2%	Shares	Other	2024-08-14
2024-03-31	$224,136	131,845	+127.1%	Shares	Other	2024-05-15
2023-09-30	$356,500	58,062	+74.8%	Shares	Other	2023-11-14
2023-03-31	$158,483	33,225	-49.8%	Shares	Other	2023-05-15
2022-12-31	$576,000	66,207	+46.5%	Shares	Other	2023-02-14
2022-09-30	$537,963	45,207	+255.5%	Shares	Other	2022-11-14
2021-09-30	$378,936	12,716	-21.5%	Shares	Sole	2021-11-15
2020-12-31	$996,031	16,193	—	Shares	Sole	2021-02-16
No filing history on record for this holder in this stock.